ASCO-GU 2024

2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium - January 25-27, 2024 / San Francisco, CA

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with High Body Mass Index

Aragon-Ching | Poster #600

Updated Results from AVENANCE: Real-World Effectiveness of Avelumab First-Line Maintenance in Patients with Advanced Urothelial Carcinoma and Analysis of Subsequent Treatment

Barthélémy | Poster #561

Subgroup Analyses from READY: REAl-World Data from an Italian Compassionate Use Program of Avelumab First-Line Maintenance Treatment for LocallY Advanced or Metastatic Urothelial Carcinoma

Bracarda | Poster #558

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Patient-Reported Outcomes in the Phase 3 JAVELIN Bladder 100 Trial

Grivas | Poster #581

Avelumab First-Line Maintenance Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: Results from the Real-World US PATRIOT-II Study

Grivas | Poster #697

Platinum Eligibility Criteria for Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in 5 European Countries

Gupta | Poster #696

Real-World Treatment Patterns and Clinical Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in Germany: Results of a Retrospective Observational Study (CONVINCE)

Machtens | Poster #551

Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States

Moon | Poster #605

A UK Real-World Observational Study of Avelumab + Axitinib in Advanced Renal Cell Carcinoma (aRCC): Outcomes at 36 Months Post Treatment Initiation

Nathan | Poster #386

Clinical Outcomes with Split-Dose Cisplatin-Based Regimens in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Systematic Literature Review and Network Meta-Analysis

O’Dwyer | Poster #589

Avelumab First-Line Maintenance in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in the Czech Republic: Interim Real-World Results from a National Reimbursement Registry

Zemankova | Poster #557

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: